Phibro Animal Health Corporation (PAHC) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Phibro Animal Health Corporation stock $31.10, price $32.96, that is 5.6% below the price, quality 54 out of 100. Rating: fairly valued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range $9.06 – $59.14 · fair‑value band $13.58 – $52.06 · the $32.96 price screens above the $31.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 5, 2026.
Follow Phibro Animal Health in your weekly email
Every Wednesday you see whether Phibro Animal Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Show moreShow less
The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers.
In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers.
Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals.
Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries.
It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors.
The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
Stock analysis
Phibro Animal Health Corporation (PAHC) currently trades at $32.96, while our model-based Fair Value estimate is $31.10, so the stock looks roughly fairly valued today (gap 6.0%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $49.35 per share, and 10 of the 25 models we run sit above the $32.96 price.
Bear case: the Asset-Based group reads lowest at $4.83, and 15 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: $13.58 (bear) to $52.06 (bull), the price of $32.96 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Phibro Animal Health Corporation reported revenue of $1.5B in FY2026 versus $942M in FY2022, a compound +12.7%/yr. Reported net income was $99.7M in FY2026, compounding +19.3%/yr from FY2022.
Key figures
Market cap $1.6B Small · P/E ratio 15.5 · P/S ratio 1.06 · EPS (TTM) $2.55 · Dividend yield 1.5% · Net margin 6.6% · Return on equity 29.7% · Return on assets (EBIT) 8.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −6%, PAHC screens cheaper than that median.
Fair Value models
Bear$13.58Fair Value $31.10Bull$52.06
Price $32.96 · Downside -5.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 4 months old). Earnings retained since then ($0.7429 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director bought shares worth $317,700, on May 29, 2026.
BuyE Thomas CorcoranDirector10,000 shares at $31.77$317,700May 29, 2026
SaleJack BendheimPresident and CEO, Director, 10% owner13× since Dec 8, 2025: 243,802 shares, avg. $50.84$12.4MMay 7, 202610b5-1 plan
SaleBFI Co., LLC10% owner16× since Nov 10, 2025: 323,926 shares, avg. $47.25$15.3MApr 16, 202610b5-1 plan
Plus 14 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+17.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Start year 2021 (pandemic). Over 10 years: +7.3% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+15.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.2%
Dividend (yield on the price)1.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.14.9% vs 4.2%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 13%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+56.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +53.2% a year for the price and +0.9% for the forecasts.
Compare Phibro Animal Health Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 6/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside−5.6% · Above median
Profitability
Return on equity (12 months)29.7% · Top 25%
Return on assets6.6% · Above median
Net margin (12 months)6.6% · Below median
Operating margin (12 months)10.6% · Below median
Growth and dividend
Revenue growth (quarter YoY)4.8% · Below median
Dividend yield (12 months)1.5% · Below median
Balance sheet
Debt / equity1.84× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Phibro Animal Health Corporation Fair Value". https://www.fairvalue-calculator.com/stock/PAHC
Frequently asked questions
Is Phibro Animal Health Corporation (PAHC) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $31.10 versus a price of $32.96, about 6% lower (fairly valued).
What is the fair value of PAHC?
Our model-based fair value for Phibro Animal Health Corporation is $31.10 (as of Nov 5, 2026), built from audited fundamentals. The current price: $32.96.
What is the quality score of PAHC?
Phibro Animal Health Corporation has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Phibro Animal Health Corporation (PAHC)?
Our model-based price target is the fair value of $31.10 (as of Nov 5, 2026) from 25 valuation models. Cautious scenario $13.58, optimistic scenario $52.06. It is a calculation from audited fundamentals, not an analyst target.
What is the Phibro Animal Health Corporation stock forecast for 2026?
Our models put fair value at $31.10, about 6% lower versus a price of $32.96 (fairly valued). Cautious scenario $13.58, optimistic scenario $52.06. The calculation is refreshed regularly with new filings.
What is the revenue of Phibro Animal Health Corporation (PAHC)?
Phibro Animal Health Corporation reported trailing-twelve-month revenue of about $1.5B (latest available figure, as of Nov 5, 2026).
Does Phibro Animal Health Corporation pay a dividend?
Phibro Animal Health Corporation currently shows a dividend yield of 1.46% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Phibro Animal Health Corporation (PAHC) and when is the ex-dividend date?
Phibro Animal Health Corporation pays a dividend of $0.48 per share a year, a dividend yield of 1.5%. The last ex-dividend date was Sep 2, 2026. A dividend has been paid every year since at least 2014. The payout ratio is 22.4% of earnings (on adjusted earnings, reported 18.8%). Free cash flow covers the dividend 0.97 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Phibro Animal Health Corporation (PAHC)?
For today's price to be fair in a discounted-cash-flow model, Phibro Animal Health Corporation would have to grow free cash flow by +56.9 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.7 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of PAHC use?
Our models discount Phibro Animal Health Corporation at 9.8 %: a base by market capitalisation (small), damped by beta 0.40, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Phibro Animal Health Corporation that is +56.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has Phibro Animal Health Corporation (PAHC) delivered so far?
Over the past 5 years revenue at Phibro Animal Health Corporation grew +12.7 % a year. The price currently implies free-cash-flow growth of +56.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Phibro Animal Health Corporation (PAHC) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Phibro Animal Health Corporation (+56.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Phibro Animal Health Corporation (PAHC)?
The free-cash-flow yield on the price is 0.73 %: that much free cash flow Phibro Animal Health Corporation produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Phibro Animal Health Corporation (PAHC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Phibro Animal Health Corporation it is $31.10 per share (as of Nov 5, 2026), against a price of $32.96. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Phibro Animal Health Corporation stock overvalued or undervalued in 2026?
As of Nov 5, 2026, PAHC trades above its calculated fair value: price $32.96, fair value $31.10, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PAHC?
No. The price is what the market pays today ($32.96); the fair value is what the company's own numbers justify ($31.10). For Phibro Animal Health Corporation the two are $1.86 per share apart. That gap is exactly why we show both numbers side by side.
How much is Phibro Animal Health Corporation worth?
The market values Phibro Animal Health Corporation at about $1.6B (market capitalisation, as of Nov 5, 2026). Per share that is $32.96; our models calculate a fair value of $31.10 per share.
What do the bullish and bearish scenarios say about PAHC?
Our models span a range for Phibro Animal Health Corporation: cautious scenario $13.58, base $31.10, optimistic $52.06 per share (as of Nov 5, 2026, price $32.96). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PAHC?
Phibro Animal Health Corporation trades at a price-to-earnings ratio of 15.5 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $31.10 is built from several models across several years. Excluding one-off items of fiscal year 2026 it is 16.2 (reported for FY2026: 13.6). Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings, FY2017, FY2024, FY2025 ex one-offs: 21.9. Other multiples: PEG 1.7, P/B 4.2, P/S 1.1, EV/EBITDA 9.2.
What is the PEG ratio of PAHC?
The PEG ratio of Phibro Animal Health Corporation is 1.68 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Phibro Animal Health Corporation (PAHC)?
Balance-sheet figures for Phibro Animal Health Corporation (as of Nov 5, 2026): return on equity 29.7%, debt of 1.84 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is PAHC from its 52-week high?
Phibro Animal Health Corporation trades at $32.96, about 44% below its 52-week high of $59.14 and 16% above the low of $28.31 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $31.10 is for.
Which stocks are comparable to Phibro Animal Health Corporation?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Phibro Animal Health Corporation stock attractive at the current price?
The data as of Nov 5, 2026: price $32.96, calculated fair value $31.10 (−6%), Quality Score 54/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PAHC calculated?
We run Phibro Animal Health Corporation through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $31.10 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Phibro Animal Health Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Phibro Animal Health Corporation (PAHC)?
The closing price on Nov 6, 2026 was $32.96. Our model-based fair value is $31.10, about 6% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Phibro Animal Health Corporation right now?
The model range is unusually wide ($13.58 to $52.06). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Where does the earnings growth of Phibro Animal Health Corporation (PAHC) come from?
Earnings per share at Phibro Animal Health Corporation grew −3.7 % a year from 2015 to 2026. Broken into its drivers: revenue per share +5.8 %, EBIT margin −2.6 %, tax rate −2.6 %, residual (interest, one-offs) −4.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Phibro Animal Health Corporation
How large is the market capitalisation of Phibro Animal Health Corporation (PAHC)?
The market capitalisation of Phibro Animal Health Corporation is $1.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Phibro Animal Health Corporation (PAHC)?
The price-to-sales ratio of Phibro Animal Health Corporation is 1.06 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Phibro Animal Health Corporation (PAHC)?
Earnings per share at Phibro Animal Health Corporation are $2.55 (price ÷ EPS = P/E 15.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Phibro Animal Health Corporation (PAHC)?
The dividend yield of Phibro Animal Health Corporation is 1.5% (payout 22.4%, on adjusted earnings, reported 18.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Phibro Animal Health Corporation (PAHC)?
The net margin of Phibro Animal Health Corporation is 6.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Phibro Animal Health Corporation (PAHC)?
The return on equity (ROE) of Phibro Animal Health Corporation is 29.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Phibro Animal Health Corporation (PAHC)?
On an EBIT basis the return on assets of Phibro Animal Health Corporation is 8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Phibro Animal Health Corporation (PAHC)?
The operating margin of Phibro Animal Health Corporation is 10.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Phibro Animal Health Corporation (PAHC)?
Revenue at Phibro Animal Health Corporation is growing +4.8% versus a year earlier (3y avg +15.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Phibro Animal Health Corporation (PAHC)?
Earnings per share at Phibro Animal Health Corporation are growing +24.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Phibro Animal Health Corporation (PAHC) carry?
The net debt of Phibro Animal Health Corporation is $727M (fiscal year 2026, ≈ 73.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Phibro Animal Health Corporation in the live analysis
One click puts Phibro Animal Health Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 5, 2026